A61K 31/49
Cinchonan derivatives
Official title: Cinchonan derivatives, e.g. quinine
A61K31/49 (Cinchonan derivatives) appears on 188 US grants and 274 published applications in this corpus.
Search patents in A61K- Granted patents
- 188
- Published applications
- 274
- Assignees
- 118
- Inventors
- 357
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 3 |
| 2003 | 5 | 24 |
| 2004 | 19 | 44 |
| 2005 | 3 | 4 |
| 2006 | 42 | 24 |
| 2007 | 2 | 5 |
| 2008 | 11 | 3 |
| 2009 | 8 | 8 |
| 2010 | 1 | 5 |
| 2011 | 2 | 6 |
| 2012 | 3 | 5 |
| 2013 | 4 | 8 |
| 2014 | 5 | 13 |
| 2015 | 2 | 6 |
| 2016 | 4 | 10 |
| 2017 | 5 | 8 |
| 2018 | 3 | 11 |
| 2019 | 3 | 15 |
| 2020 | 7 | 12 |
| 2021 | 2 | 12 |
| 2022 | 3 | 9 |
| 2023 | 2 | 14 |
| 2024 | 4 | 12 |
| 2025 | 2 | 8 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Quinine and its use to generate innate immune response29 Sep 2026US 12,746,236 B2The Trustees of the University of Pennsylvania
- Compounds for treatment of hemolysis-and inflammasome-associated diseases14 Jul 2026US 12,678,433 B2New York Blood Center, Inc.
- Dextromethorphan transdermal delivery device16 Jun 2026US 12,653,794 B2Shinkei Therapeutics, Inc.
- Use of vitamin E TPGS as a taste masking agent for bitter drugs30 Dec 2025US 12,508,315 B2Hyloris Developments SA
- Morphinan compounds3 Jun 2025US 12,319,954 B2Concert Pharmaceuticals, Inc.
- Necrosis inhibitor30 Jul 2026US 2026/0216141 A1Linkgevity Limited
- Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis9 Jul 2026US 2026/0191920 A1Holobiome, Inc.
- Tasipimidine and cyp2d6 inhibitor combination treatment9 Apr 2026US 2026/0097017 A1Orion Corporation
- Method of treating amyotrophic lateral sclerosis with pridopidine2 Apr 2026US 2026/0091028 A1Prilenia Neurotherapeutics Ltd.
- Method of treating amyotrophic lateral sclerosis with pridopidine5 Feb 2026US 2026/0034109 A1Prilenia Neurotherapeutics Ltd.
Most cited
By later US patents
- Method for reducing emotional lability154US 5,206,248 A1993
- Morphinan compounds151US 7,973,049 B2Concert Pharmaceuticals, Inc. · 2011
- Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants144US 6,207,674 B12001
- Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders143US 7,659,282 B2Avanir Pharmaceuticals · 2010
- Morphinan compounds142US 8,188,110 B2Concert Pharmaceuticals, Inc. · 2012